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XIAP Antagonist Embelin Inhibited Proliferation of
Cholangiocarcinoma Cells
Cody J. Wehrkamp, Ashley R. Gutwein, Sathish Kumar Natarajan, Mary Anne Phillippi, Justin L. Mott*
Department of Biochemistry and Molecular Biology, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States of
America

Abstract
Cholangiocarcinoma cells are dependent on antiapoptotic signaling for survival and resistance to death stimuli. Recent
mechanistic studies have revealed that increased cellular expression of the E3 ubiquitin-protein ligase X-linked inhibitor of
apoptosis (XIAP) impairs TRAIL- and chemotherapy-induced cytotoxicity, promoting survival of cholangiocarcinoma cells.
This study was undertaken to determine if pharmacologic antagonism of XIAP protein was sufficient to sensitize
cholangiocarcinoma cells to cell death. We employed malignant cholangiocarcinoma cell lines and used embelin to
antagonize XIAP protein. Embelin treatment resulted in decreased XIAP protein levels by 8 hours of treatment with maximal
effect at 16 hours in KMCH and Mz-ChA-1 cells. Assessment of nuclear morphology demonstrated a concentrationdependent increase in nuclear staining. Interestingly, embelin induced nuclear morphology changes as a single agent,
independent of the addition of TNF-related apoptosis inducing ligand (TRAIL). However, caspase activity assays revealed
that increasing embelin concentrations resulted in slight inhibition of caspase activity, not activation. In addition, the use of
a pan-caspase inhibitor did not prevent nuclear morphology changes. Finally, embelin treatment of cholangiocarcinoma
cells did not induce DNA fragmentation or PARP cleavage. Apoptosis does not appear to contribute to the effects of
embelin on cholangiocarcinoma cells. Instead, embelin caused inhibition of cell proliferation and cell cycle analysis indicated
that embelin increased the number of cells in S and G2/M phase. Our results demonstrate that embelin decreased
proliferation in cholangiocarcinoma cell lines. Embelin treatment resulted in decreased XIAP protein expression, but did not
induce or enhance apoptosis. Thus, in cholangiocarcinoma cells the mechanism of action of embelin may not be dependent
on apoptosis.
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triptolide resulted in decreased XIAP protein levels and increased
sensitivity to TRAIL [7]. Together, these data suggest that
targeting XIAP in cholangiocarcinoma cells increases sensitivity to
apoptosis. XIAP’s antiapoptotic effects are overcome upon
mitochondrial membrane permeabilization and release of
SMAC/DIABLO [8], a protein that binds the BIR3 domain of
XIAP [9,10].
The small molecule embelin has been found to inhibit XIAP
and computer modeling as well as fluorescence polarization
competition assays suggest it binds the SMAC-binding pocket of
XIAP [11]. Treatment with embelin has been shown to sensitize
cells to apoptosis through TRAIL, chemotherapy, and targeted
therapy plus cFLIP knockdown. Further, embelin treatments
decreased XIAP protein levels in leukemia cells [12]. Based on
these findings, embelin has been described as an XIAP antagonist.
However, alternate/additional mechanisms of embelin action
have been described, including inhibition of NF-kB [13] and
inhibition of Akt/mTOR/S6K1 [14].
In this study, we sought to assess the effects of embelin on XIAP
protein levels, apoptosis, and proliferation in cholangiocarcinoma

Introduction
Cholangiocarcinoma is a liver tumor with cellular features of
bile duct epithelial cells and is the second most common primary
liver cancer. Biliary tract inflammation predisposes to cholangiocarcinoma, although most patients do not have recognized
underlying liver disease at the time of diagnosis. Chemotherapy
has been shown to prolong survival, but only modestly [1], and
five-year survival remains less than 10%. This may be due to
decreased tumor cell death in response to chemotherapy. A
number of mechanisms contribute to apoptosis resistance,
including overexpression of the caspase-inhibitory protein Xlinked inhibitor of apoptosis protein (XIAP).
XIAP is an E3 ubiquitin-protein ligase that binds and inhibits
caspases 3, 7, and 9 [2,3]. XIAP is ubiquitously expressed at the
mRNA level [4] and has been shown to be induced in
cholangiocarcinoma cells by the inflammatory mediator IL-6
[5]. XIAP protects cholangiocarcinoma cells from apoptosis
induced by chemotherapeutic drugs [5] and by the death receptor
ligand TNF-related apoptosis-inducing ligand (TRAIL) [6].
Treatment of cholangiocarcinoma cells with the small molecule
PLOS ONE | www.plosone.org
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cells. While embelin decreased cellular XIAP protein levels,
caspase activity was not increased. Proliferation was inhibited by
embelin and cells were arrested in S and G2/M phases. These
observations indicate that embelin reduced tumor cell survival and
proliferation, but did not increase apoptosis.

staining and add additional evidence that the nuclear morphology
changes we initially observed were unlikely to reflect apoptosis.
Based on the known function of XIAP in inhibiting caspase
activity, it was anticipated that embelin treatment would increase
caspase activation and can increase the levels of cleaved poly
(ADP-ribose) polymerase (PARP), a marker of caspase-induced
apoptosis. Surprisingly, treatment of Mz-ChA-1 cells with embelin
did not result in increased caspase 3/7-like hydrolase activity, but
instead caused decreased caspase activation at 30 mM (Fig. 3A).
This observation was repeated in BDEneu cells, which also
showed inhibition rather than activation of caspase 3/7 (Fig. 3B).
Caspase actvity was then assessed at an earlier time point, 4 hours,
in case caspase activation was an early rather than late event.
Embelin treatment did not increase caspase activity at 4 hours,
while the positive control staurosporine caused robust caspase
activity in Mz-ChA-1 and KMCH cells (Fig. 3C). Staurosporine
did not increase caspase activity to a significant degree in HuCCT
cells, possibly indicating resistance or slower apoptosis kinetics in
HuCCT cells. To determine if embelin-induced nuclear DAPI
staining was caspase dependent, we treated BDEneu cells with
vehicle, embelin, or embelin plus the pan-caspase inhibitor ZVAD-fmk and quantified DAPI-positive nuclei. Embelin treatment resulted in nuclear changes in the presence or absence of ZVAD-fmk (Fig. 3D), consistent with morphology changes that were
not caspase-dependent. Control experiments using the same ZVAD-fmk concentration confirmed that the inhibitor blocked
caspase activity (data not shown). Next, we tested whether embelin
treatment affected total PARP protein levels or PARP cleavage in
Mz-ChA-1 cells. Clearly, there was no change in the levels of
PARP or cleaved PARP with embelin treatment (Fig. 3E).
Together, these results suggest that embelin treatment did not
alter caspase activity.
Embelin has been shown to inhibit cell proliferation in cancer
cells [20–22]. We tested the effect of embelin on Mz-ChA-1 cell
growth, using the MTT assay. Growth was significantly reduced,
initially apparent as no increase in cell number at 24 or 48 hours,
followed by a significant reduction in the number of viable cells at
72 hours in the presence of 15 mM embelin (Figure 4A). Growth
inhibition was also apparent in KMCH cells at 24–72 hours,
though to a smaller extent than in Mz-ChA-1 cells. HuCCT cells
were found to be resistant to the growth-inhibitory effects of
embelin, similar to the lack of effect of embelin on XIAP protein
content in these cells (see Fig. 1B). To further analyze the effect of
embelin on proliferation, investigation of cell cycle progression was
performed using propidium iodide staining followed by flow
cytometry. Mz-ChA-1 cells were chosen based on their response to
embelin treatment in growth assays. In vehicle-treated cells
(DMSO), 76% of cells were in the G0/G1 phase (2N), with the
remaining cells divided between S phase and G2/M (4N).
Treatment with 15 mM embelin caused cell cycle arrest and an
increase in the percentage of cells in G2/M as well as an increase
in the percentage of cells in S phase. Correspondingly, a decrease
in the number of cells in G0/G1 was observed (Fig. 4B and 4C).

Results
To assess the potential for antagonism of XIAP in cholangiocarcinoma cells, we first determined XIAP expression at the
protein level in several cell lines. XIAP protein was expressed in all
three cell lines with highest expression in Mz-ChA-1 cells and
HuCCT cells, and somewhat lower XIAP protein levels in
KMCH cells (Fig. 1A). Upon treatment with embelin, cellular
XIAP protein levels decreased with time in Mz-ChA-1 and
KMCH cells, while XIAP was essentially unchanged in HuCCT
cells treated with embelin for up to 32 hours (Fig. 1B).
We sought evidence that embelin binds directly to XIAP protein
in our cells by employing the cellular thermal shift assay [15]. This
assay is based on the observation that ligand binding often
stabilizes the cognate target protein [16–19]. The cellular thermal
shift assay measures heat-induced protein denaturation in the
absence and presence of the small molecule ligand. In this case,
lysed Mz-ChA-1 cells were incubated with vehicle or embelin and
XIAP denaturation was measured by loss of solubility upon heat
treatment. We observed that XIAP protein in cell lysates became
insoluble at about 60uC. The denaturation temperature was not
different in the presence or absence of embelin (61.0+/21.4 uC
versus 59.9+/20.7uC, respectively; p = 0.49 by t-test; Fig. 1C).
Previous studies have found that siRNA-mediated depletion of
XIAP was sufficient to sensitize cholangiocarcinoma cells to
apoptosis. We tested cell treatment with embelin or embelin plus
TRAIL in KMCH (Fig. 2A) and Mz-ChA-1 cells (Fig. 2B) by
quantifying altered nuclear morphology after staining with the
DNA-binding dye, 49-6-diamidino-2-phenylindole (DAPI). The
addition of embelin (1–10 mM) increased TRAIL-induced DAPIpositive nuclei in both cell types. Interestingly though, in Mz-ChA1 cells, embelin alone appeared to have as much effect as embelin
plus TRAIL (Fig. 2B). Additional testing of the highly tumorigenic
rat-derived BDEneu cell line also showed increased numbers of
DAPI-positive nuclei after embelin treatment (Fig. 2C). This
suggested embelin may have single-agent activity in cholangiocarcinoma cells. Single-agent activity was somewhat unexpected
and (in conjunction with the caspase data, see below) prompted us
to closely examine the nuclear staining. Untreated live Mz-ChA-1
cells stained with DAPI showed very low nuclear fluorescence
(unstained nuclei outlined), while a sporadic apoptotic nucleus
showed bright staining and obvious fragmention (Fig. 2D). Close
examination of nuclei in embelin-treated cells revealed DAPIpositive staining with local regions of bright signal, however nuclei
did not appear fragmented or condensed, and were not consistent
with apoptotic nuclei (Fig. 2E).
Because apoptosis is a process, assessment at a single time point
may not accurately capture the apoptotic signal. We have
performed a time course of DNA laddering upon embelin
treatment (4, 8, 16, and 24 hours) compared to the positive
control staurosporine over the same time. The results demonstrate
minimal DNA laddering in vehicle (DMSO) treated cells at
24 hours (Veh) that was similar to the laddering seen in embelintreated cells at 24 hours. In contrast, the kinase inhibitor
staurosporine was included as a positive control and showed rapid
formation of a DNA ladder with ,180 bp spacing, consistent with
apoptotic internucleosomal fragmentation (Fig. 2F). The results of
this experiment support the previous conclusions based on DAPI
PLOS ONE | www.plosone.org

Discussion
The results of this study relate to effects on proliferation of
cholangiocarcinoma cells upon embelin treatment. Our results
demonstrated that embelin decreased cellular XIAP protein levels,
caused a caspase-independent change in nuclear morphology,
decreased proliferation, and slowed progression through the cell
cycle. Each of these findings will be discussed below.
Embelin has been described to have numerous activities,
including antifertility [23] and analgesia [24] functions. Recently,
2
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Figure 1. Embelin caused XIAP degradation in cholangiocarcinoma cell lines. (A) Immunoblot of XIAP in untreated cholangiocarcinoma cell
lines. Actin was included as a loading control. Apparent molecular weight for each band is indicated to the right. (B) Cells were treated with 15 mM
embelin in DMSO or DMSO alone (Veh) for the indicated times. Whole cell lysates were blotted for XIAP and actin. (C) For the cellular thermal shift
assay, Mz-ChA-1 cells were lysed by freeze-thaw and then incubated with embelin (50 mM) or DMSO (Vehicle) for 30 minutes and separated into
20 mL aliquots. Aliquots were heated to the indicated temperatures and cooled to room temperature and soluble XIAP measured by immunoblot.
Band intensity was determined by densitometry of scanned films and data are plotted compared to the signal intensity observed at 45uC (100%).
Data are fitted using the Boltzman function; the dashed line indicates the fit for vehicle-treated samples, the solid line for embelin-treated samples.
Blot is representative of four replicates used in the graph.
doi:10.1371/journal.pone.0090238.g001

embelin has received attention as an antitumor agent that
promotes apoptosis [11,13,25,26] and decreases proliferation
[12,21,27,28]. In a computational screen for structures that bind
XIAP, embelin was selected for further characterization. Embelin
could compete with SMAC for XIAP binding and in prostate
tumor cells (PC3) caused loss of cell growth, increased apoptosis
(defined as annexin V-positive, propidium iodide-positive cells),
and an increased percentage of cells with activated caspase 9 [11].
In a pancreatic cancer cell line, combined treatment with an
antisense oligonucleotide to cFLIP, embelin, and TRAIL decreased cell viability compared to cFLIP antisense and TRAIL
alone in a tetrazolium-based assay [25]. Because XIAP has a
PLOS ONE | www.plosone.org

strong effect in cholangiocarcinoma cell lines to protect against cell
death, we tested the effect of embelin on XIAP protein levels in
human cholangiocarcinoma cell lines and found that embelin
caused a reduction in XIAP in Mz-ChA-1 and KMCH cells.
The differential effect of embelin treatment on XIAP protein
levels depending on the cell line tested is consistent with literature
reports. Embelin treatment of the leukemia cell line HL 60 caused
a reduction in XIAP protein levels and increased caspase 3 and
caspase 9 cleavage [12]. However, in glioma cell lines, embelin did
not significantly alter XIAP protein levels [26]. In a breast cancer
cell line overexpressing ErbB2, embelin alone decreased the
viability of cells (tetrazolium), although siRNA to XIAP did not.
3
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Figure 2. Embelin induced altered nuclear morphology in cholangiocarcinoma cell lines. (A) KMCH cells were treated for 24 hours with
TRAIL at the indicated concentrations with or without embelin (1 and 10 mM). Cells were then stained with DAPI and bright nuclei were counted as a
percentage of total nuclei. Data from one experiment are plotted as percent DAPI-positive nuclei on the vertical axis. (B) Mz-ChA-1 cells were treated
with TRAIL (4 ng/mL) or medium for 24 hours with 5 or 10 mM embelin, and DAPI-positive nuclei counted as a percent of total cells. Data are mean of
3 experiments +/2 standard error of the mean. n.s. = not significantly different. * p,0.05, ** p,0.01 by ANOVA with Bonferroni compared to medium
alone. (C) Rat BDEneu cholangiocarcinoma cells were treated with DMSO (Vehicle; open bar) or embelin (50 mM, filled bar) for 48 hours, followed by
DAPI staining. Data are mean of 3 experiments +/2 SEM. *** p,0.001 compared to vehicle, Students t-test. (D) Vehicle-treated Mz-ChA-1 cells were
stained with DAPI and imaged by epifluorescence without fixation. Healthy nuclei (indicated by grey outlines) did not stain with DAPI while a
sporadic apoptotic nucleus (arrow) was brightly stained. Bar = 10 mm. (E) DAPI-positive nuclei of Mz-ChA-1 cells treated with embelin (15 mM for
24 hours) did not show characteristic apoptotic fragmentation or pyknosis. (F) Mz-ChA-1 cells were treated with DMSO (Veh), embelin (15 mM), or
staurosporine followed by analysis of DNA fragmentation on a 2% agaraose gel. Vehicle treatmetn was for 24 hours. Embelin and staurosporine
treatments were for 4, 8, 16, and 24 hours. M = 100 bp DNA marker. The gel was stained with ethidium and photographed and the image was
inverted to show DNA as a dark signal on a light background. Images in Panel D, E, and F were adjusted for brightness and contrast to ensure that
features were visible and the entire image was treated equally.
doi:10.1371/journal.pone.0090238.g002

embelin on XIAP protein depends on the context. Similarly, the
effect on cell viability of embelin alone or in combination
treatments varies.
We next sought evidence of a direct interaction of embelin with
XIAP in our cells. We utilized the recently-described cellular
thermal shift assay [15] to assess the stability of XIAP in the
presence or absence of embelin. In our experiments, however,
embelin did not reproducibly alter the stability of XIAP. Thus, we

Combined treatment with traztuzumab (an antagonistic ErbB2
antibody) and embelin had no effect while siRNA to XIAP plus
traztuzumab increased apoptosis, suggesting that embelin does not
simply mimic loss of XIAP [29]. Embelin treatment of PC3
prostate cancer cells did not decrease XIAP protein levels, and did
not increase caspase 9 activation (alone or combined with ionizing
radiation) although there was an increase in annexin V and
propidium iodide double-positive cells [21]. Thus, the effect of

PLOS ONE | www.plosone.org
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Figure 3. Embelin partially inhibited caspase activation and did not induce caspase-dependent cell death in cholangiocarcinoma
cells. (A) Mz-ChA-1 cells were treated with embelin for 24 hours and caspase 3/7 activity measured biochemically. Untreated cells were used for
comparison and caspase activity in untreated cells normalized at 1.0. (B) BDEneu cells were treated with embelin (48 hours) and caspase 3/7 activity
measured. (C) Caspase 3/7 activity was measured at an earlier time point (4 hours) in Mz-ChA-1, KMCH, and HuCCT cells to test for early caspase
activation. Following 4 hours of vehicle, embelin (15 mM) or staurosporine (1 mg/mL), caspase 3/7 activity was measured biochemically. (D) BDEneu
cells treated with 50 mM embelin for 48 hours were assayed for DAPI-positive nuclei with and without co-treatment with the caspase inhibitor Z-VADfmk (50 mM). DAPI-positive nuclei are presented as percent of total cells, n = 3, mean +/2 SEM. Comparison of embelin versus embelin+Z-VAD-fmk
was not significantly different. Panels A, B, C & D data are mean of 3 or 4 experiments +/2 SEM; ** p,0.01, *** p,0.001 versus vehicle, ANOVA with
Bonferroni correction. (E) Mz-ChA-1 cells were treated with embelin (5–15 mM) in DMSO or DMSO alone (Veh) for 24 hours. Whole cell lysates were
blotted for PARP. Actin was included as a loading control. Apparent molecular weight for each protein is indicated to the right.
doi:10.1371/journal.pone.0090238.g003

staining as increased fragmentation, compaction of the nuclear
signal, and increased staining intensity. Indeed, an advantage of
using DAPI as a DNA stain in apoptosis measurement is the
observation that many viable cells exclude the dye but dying cells
take up DAPI and fluoresce brightly, thus providing a strong signal
with low background staining of viable nuclei. Notably, some
living cells take up DAPI, possibly through the transporters
organic cation transporter-1 (OCT1) [31] and multidrug and toxin
extrusion proteins (MATE1 and MATE2) [32], and most cells will
gradually accumulate DAPI over time. Thus, a brightly stained
nucleus is not definitive evidence of apoptosis. Additional
morphological features can be used then to distinguish brightlystained living cells from brightly-stained apoptotic cells, including
fragmentation and condensation of the nucleus. Altered nuclear
morphology is also observed during different phases of the mitotic
or meiotic cell cycle (e.g., see [33] and [34]) and with different
chromatin state (heterochromatin versus euchromatin). Thus, an
alternate measure of apoptosis is important, such as DNA
fragmentation, biochemical assessment of caspase activity, and
immunoblot analysis of cleaved PARP levels. Importantly, in our

were unable to confirm direct binding. This can be interpreted
either as a lack of direct binding, or that binding does not
significantly stabilize XIAP structurally. In previous heteronuclear
single quantum coherence spectroscopy experiments, embelin was
found to alter the spectrum of the XIAP BIR3 domain, suggesting
a physical interaction [11]. The lack of stabilization in the complex
cell lysate (this study) does not rule out a direct interaction, and
similarly, observation of a direct binding interaction in a single
component system does not answer the question of binding in the
cellular environment.
Based on the role of XIAP in preventing cholangiocarcinoma
cell apoptosis, we hypothesized that embelin would increase cell
death in combination with TRAIL. Initial experiments indeed
showed that an increased percentage of cells had altered nuclear
morphology upon embelin treatment, measured by the DNA dye
DAPI. However, careful analysis confirmed that the altered
morphology did not reflect increased apoptotic nuclei. Binding of
DAPI to DNA is known to result in increased fluorescent signal
over soluble unbound DAPI [30]. Altered nuclear morphology is a
hallmark of apoptosis, and can be easily visualized by DAPI

PLOS ONE | www.plosone.org
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Figure 4. Inhibition of proliferation and cell cycle arrest by embelin. (A) Cell proliferation was measured by MTT and cell number measured
by absorbance at 540 nm (Abs 540 nm). Signal represents the mean (n = 4) +/2 standard error of the mean, normalized to the starting value (day 0,
set at 100%). Cells treated with embelin (15 mM) are plotted with a solid line and filled symbols and vehicle-treated cells are plotted with a dashed line
and open symbols. ** p,0.01 and *** p,0.001 versus vehicle at the same time point, ANOVA with Bonferroni correction. Values for HuCCT were not
significantly different at any time point. (B) Cell cycle analysis of Mz-ChA-1 cells was performed by propidium iodide staining followed by flow
cytometry. A histogram of propidium iodide stained cells is shown for DMSO-treated and embelin-treated cells (15 mM, 24 hours). (C) Quantitation of
the percentage of cells with 2N or 4N nuclear DNA content, and cells that are in S phase (DNA content intermediate between 2N and 4N).
Representative experiment of 3 independent treatments.
doi:10.1371/journal.pone.0090238.g004

manifested initially as growth arrest at 24 hours. Mz-ChA-1 cells
failed to proliferate after this arrest and eventually viability was
lost. In KMCH, after the initial 24 hours, the rate of proliferation
remained lower than vehicle-treated cells but was not completely
halted. HuCCT cells appeared to be resistant to embelin-induced
growth arrest. This pattern of strong inhibition in Mz-ChA-1,
intermediate inhibition in KMCH, and no effect in HuCCT cells
parallels the data on XIAP protein levels. Cell cycle analysis of
Mz-ChA-1 cells confirmed an effect of embelin on cell cycle
progression, and revealed more cells in S and G2/M phases. This
effect is similar to the growth inhibition in PC3 cells where
embelin caused a reduction in cells in G0/G1 and increased
numbers in S phase and G2/M phase [21]. An increase in the
number of cells in the later stages of the cell cycle can be consistent
with either increased proliferation, or decreased proliferation due
to a late-stage block or slowing in the cell cycle. For instance, cells
treated with topoisomerase inhibitor have decreased proliferation

cells, embelin treatment did not induce DNA fragmentation and
caused inhibition, not activation of caspases, and did not increase
the levels of cleaved PARP. Further, inhibition of caspase activity
did not alter embelin-induced nuclear staining. Thus, we interpret
the altered nuclear morphology to reflect nuclear changes
unrelated to apoptosis, possibly due to altered cell cycle or
increased cellular DAPI uptake.
Despite decreasing XIAP embelin treatment did not increase
cell death. It is possible that XIAP levels were not sufficiently
decreased to disinhibit apoptosis. Alternatively, embelin may have
pleiotropic effects on cell death that mask sensitization. Moreover,
XIAP may not play a dominant role in apoptosis protection in
these cholangiocarcinoma cell lines. This latter explanation seems
less likely based on our previous experiments showing that siRNA
against XIAP caused increased apoptosis and increased caspase
activity in KMCH cholangiocarcinoma cells [6].
Cholangiocarcinoma cell lines exhibited growth inhibition upon
treatment with embelin. In Mz-ChA-1 and KMCH cells this was

PLOS ONE | www.plosone.org
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and an increased percentage of cells are in both S phase and G2/
M (e.g., [35]), consistent with activation of a late checkpoint.
In conclusion, our results demonstrated sensitivity of cholangiocarcinoma cells to treatment with embelin, which resulted in
inhibition of cell cycle progression and slowed proliferation. We
did not observe increased spontaneous or TRAIL-induced
apoptosis in embelin-treated cells, despite reduced XIAP protein
levels. In this regard, embelin did cause an alteration in nuclear
staining that was initially taken by us to reflect apoptosis.
Additional studies on caspase activation as well as cell-by-cell
analysis of staining instead revealed altered staining but no
increase in characteristic apoptotic nuclear features. Embelin may
cause altered cellular uptake of DAPI as untreated healthy cells did
not take up this DNA-binding dye. In addition, the effect of
embelin to delay cell cycle progression may have resulted in a
higher percentage of nuclei in various stages of mitosis manifesting
altered nuclear morphology. The late loss of cells that was
observed in tetrazolium-based proliferation assays (e.g., Figure 4A
at 72 hours) may reflect mitotic collapse, apoptosis, or necrosis.
Taken together, our data suggest that embelin may have a growth
inhibitory effect in cholangiocarcinoma, but to promote tumor cell
apoptosis additional treatments are required.

divided into identical aliquots which were incubated with either
embelin (50 mM) or an equal volume of DMSO for 30 minutes
and were then heated for 3 minutes on a gradient thermal cycler.
The lower temperature was set at 46uC and the higher
temperature was at 70uC. Heated samples were then cooled at
room temperature for 3 minutes and centrifuged at 13,000 g for
20 minutes to pellet denatured protein aggregates. Supernatants
were analyzed by SDS-PAGE and immunoblot for XIAP.

Nuclear Morphology Assay
Treated cells were stained with DAPI (5 mg/mL final) for
20 minutes at 37uC prior to imaging by epifluorescence (Leica
DMI6000B). Cells were counted as DAPI-positive if the nucleus
showed bright staining, and as apoptotic if there was characteristic
nuclear fragmentation, blebbing, or pyknosis. Total cell number
was determined in the same field by phase contrast microscopy,
and data are expressed as a percent of DAPI-positive nuclei out of
total.

DNA fragmentation assay
Mz-ChA-1 cells were treated with vehicle (DMOS), embelin
(15 mM), or staurosporine (1 mg/mL) for 4–24 hours. Fragmented
DNA was then isolated essentially following the protocol of
Shiraishi et al. [40], except that DNA was extracted by
phenol:chloroform:isoamyl alcohol prior to RNase A treatment.
DNA was run on a 2% agarose gel and visualized by ethidium
bromide staining. The image was then digitally inverted and
brightness optimized without altering other aspects of the image.

Materials and Methods
Cell Culture and Treatment
Human malignant cholangiocarcinoma cell lines used in this
study were KMCH [36], Mz-ChA-1 [37], and HuCCT cells [38].
The highly tumorigenic rat cholangiocarcinoma cell BDEneu was
a kind gift from Alphonse Sirica (Virginia Commonwealth
University) [39]. Human cells were grown in DMEM with high
glucose supplemented with 10% (v/v) fetal bovine serum (FBS),
penicillin (100 U/ml), streptomycin (100 mg/ml), G418 (50 mg/
ml), and insulin (0.5 mg/ml) at 37uC with 5% CO2 in a humidified
chamber. BDEneu cells were grown in DMEM supplemented with
10% FBS, human transferrin (5 mg/ml), and insulin (0.5 mg/ml).
Embelin was from Sigma-Aldrich and was resuspended in
dimethylsulfoxide (DMSO). Staurospirine was from Fisher and
was used at 1 mg/mL final concentration. Cells were treated with
0–50 mM embelin for 2–48 hours, as indicated in the figure
legends, and compared to DMSO-treated cells (vehicle). Recombinant human TRAIL was obtained from R&D Systems and used
at a final concentration of 4–8 ng/mL.

Caspase 3/7 Assay
Cells were seeded in a 96-well plate and caspase 3/7 activity
measured by enzymatic cleavage of a fluorogenic substrate using
ApoOne Homogeneous Caspase 3/7 Assay (Promega). The pancaspase inhibitor Z-VAD-fmk was purchased from Sigma-Aldrich
and resuspended in DMSO. Final working concentration was
50 mM.

Proliferation and Cell Cycle
Cell proliferation was assayed by reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Invitrogen). MTT was freshly dissolved into PBS at a stock
concentration of 12 mM and diluted into phenol-free DMEM
with 10% FBS for a final MTT concentration of 2 mM. Reactions
were carried out at 37uC for four hours and stopped by removing
the medium. Reduced MTT was dissolved in 100 mL isopropanol
and absorbance measured at 540 nm. All data are corrected to the
initial signal, set at 100%. Assays were repeated four times for each
condition.

Immunoblotting
Treated cells were lysed in 50 mM Tris-HCl (pH 7.4), 150 mM
sodium chloride, 1 mM ethylenediamine tetraacetic acid, 1 mM
dithiothreitol, 1 mM sodium orthovanadate, 100 mM sodium
fluoride, and 1% triton X-100 (w/v) supplemented with Complete
protease inhibitors. After lysis, insoluble proteins were removed by
centrifugation and lysate was separated by sodium dodecylsulfatepolyacrylamide gel electrophoresis (SDS-PAGE), transferred to
nitrocellulose, and probed for XIAP or actin. Mouse anti-XIAP
antibody (#610717) was from BD Biosciences, and anti-actin
antiserum was from SantaCruz. Rabbit anti-PARP antibody
(#9542) was from Cell Signaling.

Statistical Analysis
Data were analyzed by ANOVA with post-hoc Bonferroni
correction when multiple comparisons were possible. When only
two conditions were measured, student’s t-test was employed.
Groups were considered significantly different when the p-value
was less than or equal to 0.05.

Cellular thermal shift assay

Author Contributions

Mz-ChA-1 cells were grown to 80% confluence and lysed in
PBS containing Complete protease inhibitors by three cycles of
freeze-thaw (liquid nitrogen), as described [15]. Cell debris was
pelleted by centrifugation (13,000 g for 20 minutes). Lysates were
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